OBJECTIVE: To assess the immunosuppressive effect of R-CHOP in patients with B-cell lymphoma at 2 years. METHODS: Parameters of humoral and cell-mediated immunity were assessed in 89 patients with diffuse large B-cell lymphoma or follicular lymphoma before and after 6-8 cycles of R-CHOP-14 or R-CHOP-21 regimen. RESULTS: Data on pre- and posttreatment serum IgG (sIgG) levels were available for all 89 patients, while the corresponding data on serum CD20+, CD3+, CD4+, and CD8+ lymphocyte counts were available in only 43. Median sIgG levels significantly decreased from 1,221 mg/dl (baseline) to 733 mg/dl (after chemotherapy) (p < 0.001). Although CD20+ and CD4+ cell counts decreased (p < 0.001), no significant effect of chemotherapy on CD3+ and CD8+ cell counts was observed. CD20+ cell counts were restored to baseline levels at the 12-month follow-up. sIgG levels and CD4+ cell counts were not completely restored at 24 months, indicating a sustained immunosuppressive effect of R-CHOP in these patients. The incidence of infections over the 2-year period was 16.3-23.6%. CONCLUSION: The immunosuppressive effect of R-CHOP in newly diagnosed cases of B-cell lymphoma tends to persist for >2 years, although sIgG levels were restored more quickly than CD4+ cell counts.
OBJECTIVE: To assess the immunosuppressive effect of R-CHOP in patients with B-cell lymphoma at 2 years. METHODS: Parameters of humoral and cell-mediated immunity were assessed in 89 patients with diffuse large B-cell lymphoma or follicular lymphoma before and after 6-8 cycles of R-CHOP-14 or R-CHOP-21 regimen. RESULTS: Data on pre- and posttreatment serum IgG (sIgG) levels were available for all 89 patients, while the corresponding data on serum CD20+, CD3+, CD4+, and CD8+ lymphocyte counts were available in only 43. Median sIgG levels significantly decreased from 1,221 mg/dl (baseline) to 733 mg/dl (after chemotherapy) (p < 0.001). Although CD20+ and CD4+ cell counts decreased (p < 0.001), no significant effect of chemotherapy on CD3+ and CD8+ cell counts was observed. CD20+ cell counts were restored to baseline levels at the 12-month follow-up. sIgG levels and CD4+ cell counts were not completely restored at 24 months, indicating a sustained immunosuppressive effect of R-CHOP in these patients. The incidence of infections over the 2-year period was 16.3-23.6%. CONCLUSION: The immunosuppressive effect of R-CHOP in newly diagnosed cases of B-cell lymphoma tends to persist for >2 years, although sIgG levels were restored more quickly than CD4+ cell counts.
Authors: D G Maloney; A J Grillo-López; D J Bodkin; C A White; T M Liles; I Royston; C Varns; J Rosenberg; R Levy Journal: J Clin Oncol Date: 1997-10 Impact factor: 44.544
Authors: Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny Journal: Blood Date: 2004-02-19 Impact factor: 22.113
Authors: Daniel O Persky; Joseph M Unger; Catherine M Spier; Baldassarre Stea; Michael LeBlanc; Matthew J McCarty; Lisa M Rimsza; Richard I Fisher; Thomas P Miller Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: John H Baird; David J Epstein; John S Tamaresis; Zachary Ehlinger; Jay Y Spiegel; Juliana Craig; Gursharan K Claire; Matthew J Frank; Lori Muffly; Parveen Shiraz; Everett Meyer; Sally Arai; Janice Wes Brown; Laura Johnston; Robert Lowsky; Robert S Negrin; Andrew R Rezvani; Wen-Kai Weng; Theresa Latchford; Bita Sahaf; Crystal L Mackall; David B Miklos; Surbhi Sidana Journal: Blood Adv Date: 2021-01-12
Authors: Francesco Marchesi; Giulia Regazzo; Francesca Palombi; Irene Terrenato; Andrea Sacconi; Manuela Spagnuolo; Sara Donzelli; Mirella Marino; Cristiana Ercolani; Anna Di Benedetto; Giovanni Blandino; Gennaro Ciliberto; Andrea Mengarelli; Maria Giulia Rizzo Journal: J Exp Clin Cancer Res Date: 2018-05-02